The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
Open accessAbstract
Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These populations have an underlying predisposition to deficient insulin secretion, which has a key role in the pathogenesis of T2DM. Indian and Chinese people might be more susceptible to hepatic or skeletal muscle insulin resistance, respectively, than other populations, resulting in specific forms of insulin deficiency. Cluster-based phenotypic analyses demonstrate a higher frequency of severe insulin-deficient diabetes mellitus and younger ages at diagnosis, lower β-cell function, lower insulin resistance and lower BMI among Indian and Chinese people compared with European people. Individuals diagnosed earliest in life have the most aggressive course of disease and the highest risk of complications. These characteristics might contribute to distinctive responses to glucose-lowering medications. Incretin-based agents are particularly effective for lowering glucose levels in these populations; they enhance incretin-augmented insulin secretion and suppress glucagon secretion. Sodium–glucose cotransporter 2 inhibitors might also lower blood levels of glucose especially effectively among Asian people, while α-glucosidase inhibitors are better tolerated in east Asian populations versus other populations. Further research is needed to better characterize and address the pathophysiology and phenotypes of T2DM in Indian and Chinese populations, and to further develop individualized treatment strategies. Prevalence of type 2 diabetes mellitus (T2DM) is increasing substantially in India and China. This Review discusses the epidemiology, phenotypes and pathogenesis of T2DM in India and China and evaluates options for optimal pharmacological management. India and China account for nearly half of the global number of people with type 2 diabetes mellitus (T2DM), and incidence rates are rising rapidly among young people. Indian and Chinese people seem to have increased susceptibility to reduced insulin secretion, which probably has a stronger or more frequent role than insulin resistance in the pathogenesis of T2DM than in other populations. In many Indian people, deficient first-phase insulin secretion and increased hepatic insulin resistance result in impaired fasting glucose, while in many Chinese people, deficient first-phase and second-phase insulin secretion and increased skeletal muscle insulin resistance result in impaired glucose tolerance. Cluster-based phenotypic analyses demonstrate a higher frequency of severe insulin-deficient diabetes mellitus and demonstrate generally younger ages at diagnosis, lower β-cell function, lower insulin resistance and lower BMI among Indian people and Chinese people compared with European people. Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists improve pancreatic β-cell function and reduce blood levels of glucose especially effectively in Indian and Chinese people compared with other populations. Sodium–glucose cotransporter 2 inhibitors might lower blood levels of glucose more effectively in Asian people than in European people, while α-glucosidase inhibitors are better tolerated among east Asian people than in other populations. India and China account for nearly half of the global number of people with type 2 diabetes mellitus (T2DM), and incidence rates are rising rapidly among young people. Indian and Chinese people seem to have increased susceptibility to reduced insulin secretion, which probably has a stronger or more frequent role than insulin resistance in the pathogenesis of T2DM than in other populations. In many Indian people, deficient first-phase insulin secretion and increased hepatic insulin resistance result in impaired fasting glucose, while in many Chinese people, deficient first-phase and second-phase insulin secretion and increased skeletal muscle insulin resistance result in impaired glucose tolerance. Cluster-based phenotypic analyses demonstrate a higher frequency of severe insulin-deficient diabetes mellitus and demonstrate generally younger ages at diagnosis, lower β-cell function, lower insulin resistance and lower BMI among Indian people and Chinese people compared with European people. Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists improve pancreatic β-cell function and reduce blood levels of glucose especially effectively in Indian and Chinese people compared with other populations. Sodium–glucose cotransporter 2 inhibitors might lower blood levels of glucose more effectively in Asian people than in European people, while α-glucosidase inhibitors are better tolerated among east Asian people than in other populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Cited by
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Self-citationKiyosue, A., Dunn, J. P., Cui, X., Hickey, A., Hirase, T., Imaoka, T., & Heine, R. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14952 · Cited by 30
Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y. (2023) · International Journal of Endocrinology · doi:10.1155/2023/9926462 · Cited by 26
Ding, J., Luo, Y., Shi, H., Chen, R., Luo, S., Yang, X., Xiao, Z., Liang, B., Yan, Q., Xu, J., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14069 · Cited by 9
Metadata
- Authors
- Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R.
- Venue
- Nature Reviews Endocrinology
- Published
- 2022-05-04
- Volume
- 18
- Issue
- 7
- Pages
- 413-432
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4225399996
- Cited by
- 239
- References
- 55
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. https://app.cochat.ai/papers/10.1038/s41574-022-00669-4
- The paper
- Ke, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R. (2022). Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-022-00669-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.